glp-1 employer coverage news october 2025 Employers across America are dropping weight-loss drug as costs explode, leaving employees to choose between health and finances. Read more below Harvard Business Review | A

California is going the biggest, investing $12 billion over five years to provide a slew of new services, from intensive case management to help people with severe behavioral health conditions to housing and food assistance through a pair of federal waivers

Looking ahead, Peptide Centre is committed to expanding our offerings, improving our services, and continuing to build long-lasting relationships with researchers and institutions worldwide

Semaglutide is a GLP-1 agonist currently used to treat type 2 diabetes and for weight management via subcutaneous injection or taken orally

This product may not be used as a pharmaceutical or veterinary drug, agricultural product, or food additive